ROR1 and prostate cancer: Zilovertamab (formerly known as cirmtuzumab or UC‐961) is a monoclonal antibody to ROR1 and is in clinical trials for the treatment of leukaemias and other cancers, such as prostate cancer and lung cancer.42, 43